THE RATIONAL USE OF THE GLP-1 ANALOGUE SEMAGLUTIDE

Abstract

This study sought to understand the role of pharmacists in the use of GLP-1 (Glucagon-Like Peptide 1) analogs in the treatment of type 2 diabetes and obesity, as well as their main side effects and their impact on patients' health. The methodology used was a bibliographic review, in which data collection and information structuring were used through books and digital scientific platforms, including Google Scholar, Scientific Electronic Library Online (SCIELO) and Pubmed, in Spanish, Portuguese and English. As a result, it was possible to understand the contribution made by the use of semaglutide and the interventions and support provided by pharmacists in promoting practices for the rational use of semaglutide, thus contributing to improving the care of overweight patients with type 2 diabetes.